Trial Profile
A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01 Combination Product in Subjects With Type 1 Diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms STEP ONE
- Sponsors ViaCyte
- 29 Nov 2021 Status changed from active, no longer recruiting to discontinued.(The study was stopped due to Insufficient functional product engraftment 0
- 10 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Jun 2021.
- 10 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2021.